Reuters logo
BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain
October 6, 2017 / 7:10 PM / in 2 months

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

Oct 6 (Reuters) - Flexion Therapeutics Inc

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

* Says ‍product label also includes positive data from type 2 diabetes study​

* Says ‍commercial supply expected to be available by late October following recent completion of manufacturing process validation​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below